Need To Know: The Consensus Just Cut Its Cohance Lifesciences Limited (NSE:COHANCE) Estimates For 2027

Market forces rained on the parade of Cohance Lifesciences Limited (NSE:COHANCE) shareholders today, when the analysts downgraded their forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the downgrade, the latest consensus from Cohance Lifesciences' nine analysts is for revenues of ₹22b in 2027, which would reflect a reasonable 3.4% improvement in sales compared to the last 12 months. Per-share earnings are expected to jump 96% to ₹5.45. Before this latest update, the analysts had been forecasting revenues of ₹25b and earnings per share (EPS) of ₹5.45 in 2027. So there's been a clear change in analyst sentiment in the recent update, with the analysts making a measurable cut to revenues and reconfirming their earnings per share estimates.

See our latest analysis for Cohance Lifesciences

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 6.8% growth on an annualised basis. That is in line with its 8.3% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 12% per year. So it's pretty clear that Cohance Lifesciences is expected to grow slower than similar companies in the same industry.

The Bottom Line

The most obvious conclusion from this consensus update is that there's been no major change in the business' prospects in recent times, with analysts holding earnings per share steady, in line with previous estimates. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Cohance Lifesciences' revenues are expected to grow slower than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Cohance Lifesciences after today.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Cohance Lifesciences analysts - going out to 2029, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.